0.67

5.63% -0.04

After Hours: .70 0.03 +4.48%

Alzamend Neuro Inc (ALZN)

Overview News Price History Financials Why ALZN Down? Discussions Forecast Stock Split

Alzamend Neuro Inc stock is traded at $0.67, with a volume of 142.17K. It is down -5.63% in the last 24 hours and down -25.13% over the past month. Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Previous Close:

$0.71

Open:

$0.72

24h Volume:

142.17K

Relative Volume:

0.40

Market Cap:

$5.21M

Revenue:

Net Income/Loss:

$-5.85M

P/E Ratio:

-0.1002

EPS:

-6.6877

Net Cash Flow:

$-8.00M

1W Performance:

-12.99%

1M Performance:

-25.13%

6M Performance:

-59.15%

1Y Performance:

-90.75%

1-Day Range:

$0.6667

$0.73

1-Week Range:

$0.6667

$0.8395

52-Week Range:

$0.6427

$15.06

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name

Alzamend Neuro Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

844-722-6333

Address

3500 LENOX RD. NE, ATLANTA

Employee

Twitter

Next Earnings Date

2024-09-12

Latest SEC Filings

ALZN's Discussions on Twitter

Compare ALZN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALZN Alzamend Neuro Inc	0.67	5.21M	0	-5.85M	-8.00M	-6.6877
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy

Alzamend Neuro Inc Stock (ALZN) Latest News

Apr 08, 2025

Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Apr 08, 2025

Mar 30, 2025

Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World

Mar 30, 2025

Mar 28, 2025

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025

Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia

Mar 27, 2025

Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India

Mar 27, 2025

Mar 26, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India

Mar 26, 2025

Mar 25, 2025

Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times

Mar 25, 2025

Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan

Mar 25, 2025

Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia

Mar 24, 2025

Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com

Mar 24, 2025

Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India

Mar 20, 2025

Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK

Mar 20, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India

Mar 20, 2025

Mar 19, 2025

Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa

Mar 18, 2025

Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq

Mar 18, 2025

Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire

Mar 18, 2025

Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan

Mar 18, 2025

Mar 17, 2025

Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World

Mar 17, 2025

Mar 15, 2025

Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia

Mar 15, 2025

Mar 14, 2025

Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com

Mar 14, 2025

Mar 13, 2025

Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World

Mar 13, 2025

Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia

Mar 11, 2025

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace

Mar 11, 2025

Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa

Mar 11, 2025

Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com

Mar 11, 2025

Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan

Mar 11, 2025

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga

Mar 11, 2025

Mar 10, 2025